Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

被引：120

作者：

Schuster, Stephen J. ^{[1
]}

Bartlett, Nancy L.

Assouline, Sarit ^{[2
]}

Yoon, Sung-Soo ^{[3
]}

Bosch, Francesc ^{[4
]}

Sehn, Laurie H. ^{[5
,6
]}

Cheah, Chan Y. ^{[7
,8
]}

Shadman, Mazyar ^{[9
]}

Gregory, Gareth P. ^{[10
,11
]}

Ku, Matthew ^{[12
]}

Wei, Michael C. ^{[13
]}

Yin, Shen ^{[13
]}

Kwan, Antonia ^{[13
]}

Yousefi, Kasra ^{[14
]}

Hernandez, Genevive ^{[13
]}

Li, Chi-Chung ^{[13
]}

O'Hear, Carol ^{[13
]}

Budde, Lihua E. ^{[15
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[2] Jewish Gen Hosp, Montreal, PQ, Canada

[3] Seoul Natl Univ Hosp, Seoul, South Korea

[4] Univ Hosp Vall dHebron, Barcelona, Spain

[5] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[6] Univ British Columbia, Vancouver, BC, Canada

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[10] Monash Hlth, Clayton, Vic, Australia

[11] Monash Univ, Sch Clin Sci, Monash Hlth, Clayton, Vic, Australia

[12] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[13] Genentech Inc, San Francisco, CA 94080 USA

[14] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[15] City Hope Natl Med Ctr, Duarte, CA USA

来源：

关键词：

D O I：

10.1182/blood-2019-123742

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5